Douwe F. Samplonius

1.4k citations

39 papers · 1.1k indexed · h-index 21

Immunology top 5%
- Immune Cell Function and Interaction 7
- Immunotherapy and Immune Responses 7
Oncology top 10%
- CAR-T cell therapy research 10
- Cancer Immunotherapy and Biomarkers 7
Biotechnology top 10%
Physiology top 10%
Radiology, Nuclear Medicine and Imaging top 10%
- Monoclonal and Polyclonal Antibodies Research 5
- Radiopharmaceutical Chemistry and Applications 4
Molecular Biology
- Cell death mechanisms and regulation 10
- RNA Interference and Gene Delivery 4

Co-authors: Wijnand Helfrich Edwin Bremer Lou F. M. H. de Leij Bram ten Cate Robert J. van Ginkel Marco de Bruyn Valerie R. Wiersma Lou de Leij
Cited by: Immunology Oncology Biotechnology
Journals: Journal of Biological Chemistry (1 paper)Blood (1 paper)PLoS ONE (1 paper)
Partner nations: Netherlands China United Kingdom

In The Last Decade

Douwe F. Samplonius

38 papers receiving 1.1k citations

Peers

Countries citing papers authored by Douwe F. Samplonius

Since Specialization

Citations

This map shows the geographic impact of Douwe F. Samplonius's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douwe F. Samplonius with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douwe F. Samplonius more than expected).

Fields of papers citing papers by Douwe F. Samplonius

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douwe F. Samplonius. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douwe F. Samplonius. The network helps show where Douwe F. Samplonius may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Douwe F. Samplonius, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douwe F. Samplonius Line = papers co-authored together Douwe F. Samplonius links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Enhancing the Anticancer Activity of a Carcinoma-Directed Peptide–HLA-I Fusion Protein by Armoring with Mutein IFNα International Journal of Molecular Sciences ·Douwe F. Samplonius,Anne Paulien van Wijngaarden,Lisanne Koll,Xiurong Ke,Wijnand Helfrich	2025	0
2	Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selectively eliminate carcinoma cells OncoImmunology ·Isabel Britsch,Anne Paulien van Wijngaarden,Xiurong Ke,Mark A.J.M. Hendriks,Douwe F. Samplonius,Emily M. Ploeg,Wijnand Helfrich	2023	3
3	A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer Cancers ·Emily M. Ploeg,Isabel Britsch,Anne Paulien van Wijngaarden,Xiurong Ke,Mark A.J.M. Hendriks,Douwe F. Samplonius,Wijnand Helfrich	2023	2
4	Synthesis and Evaluation of ¹⁸F-Enzalutamide, a New Radioligand for PET Imaging of Androgen Receptors: A Comparison with 16β-¹⁸F-Fluoro-5α-Dihydrotestosterone Journal of Nuclear Medicine ·Inês F. Antunes,Rutger J. Dost,Hilde Hoving,Aren van Waarde,Rudi Dierckx,Douwe F. Samplonius,Wijnand Helfrich,Philip H. Elsinga,Erik F. J. de Vries,Igle J. de Jong	2021	8
5	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade Journal of Investigative Dermatology ·Iris Koopmans,Mark A.J.M. Hendriks,Robert J. van Ginkel,Douwe F. Samplonius,Edwin Bremer,Wijnand Helfrich	2019	22
6	Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition Oncogene ·H. Rudolf de Boer,Martin Pool,Esméé Joosten,Marieke Everts,Douwe F. Samplonius,Wijnand Helfrich,Harry J.M. Groen,Suzanne van Cooten,Fabrizia Fusetti,Rudolf S.N. Fehrmann,Elisabeth G.E. de Vries,Marcel A.T.M. van Vugt	2018	10
7	A versatile pretargeting approach for tumour-selective delivery and activation of TNF superfamily members Scientific Reports ·Yuan He,Peter E. van Bommel,Douwe F. Samplonius,Edwin Bremer,Wijnand Helfrich	2017	6
8	Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction OncoImmunology ·Djoke Hendriks,Yuan He,Iris Koopmans,Valerie R. Wiersma,Robert J. van Ginkel,Douwe F. Samplonius,Wijnand Helfrich,Edwin Bremer	2016	36
9	CD20⁺T cells have a predominantly Tc1 effector memory phenotype and are expanded in the ascites of patients with ovarian cancer OncoImmunology ·Marco de Bruyn,Valerie R. Wiersma,Maartje C.A. Wouters,Douwe F. Samplonius,Harry Klip,Wijnand Helfrich,Hans W. Nijman,Paul Eggleton,Edwin Bremer	2015	25
10	C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity mAbs ·Valerie R. Wiersma,Marco de Bruyn,Ce Shi,Marloes J.M. Gooden,Maartje C.A. Wouters,Douwe F. Samplonius,Djoke Hendriks,Hans W. Nijman,Yunwei Wei,Jin Zhou,Wijnand Helfrich,Edwin Bremer	2015	23
11	Galectin-9 Activates and Expands Human T-Helper 1 Cells PLoS ONE ·Marloes J.M. Gooden,Valerie R. Wiersma,Douwe F. Samplonius,Jurjen Gerssen,Robert J. van Ginkel,Hans W. Nijman,Mitsuomi Hirashima,Toshiro Niki,Paul Eggleton,Wijnand Helfrich,Edwin Bremer	2013	49
12	Selective elimination of pathogenic synovial fluid T-cells from Rheumatoid Arthritis and Juvenile Idiopathic Arthritis by targeted activation of Fas-apoptotic signaling Immunology Letters ·Edwin Bremer,Wayel H. Abdulahad,Marco de Bruyn,Douwe F. Samplonius,Cees G. M. Kallenberg,Wineke Armbrust,Els Brouwers,Harald Wajant,Wijnand Helfrich	2011	15
13	Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells Clinical Cancer Research ·Marco de Bruyn,Yunwei Wei,Valerie R. Wiersma,Douwe F. Samplonius,Harry Klip,Ate G.J. van der Zee,Baofeng Yang,Wijnand Helfrich,Edwin Bremer	2011	33
14	A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability Leukemia ·Bram ten Cate,Edwin Bremer,Marco de Bruyn,Theo Bijma,Douwe F. Samplonius,Michael Schwemmlein,Gerwin Huls,G H Fey,Wijnand Helfrich	2009	50
15	Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells Journal of Molecular Medicine ·Edwin Bremer,Marco de Bruyn,Douwe F. Samplonius,Theo Bijma,Bram ten Cate,Lou F. M. H. de Leij,Wijnand Helfrich	2008	26
16	The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors Journal of Neuro-Oncology ·Jos M.A. Kuijlen,Bart J. de Haan,Wijnand Helfrich,J. de Boer,Douwe F. Samplonius,Jan Jakob A. Mooij,Paul de Vos	2006	18
17	The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells Leukemia ·Bram ten Cate,Douwe F. Samplonius,Theo Bijma,L.F.M.H. de Leij,Wijnand Helfrich,Edwin Bremer	2006	37
18	Simultaneous Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling and Enhanced Activation of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor-mediated Apoptosis Induction by an scFv:sTRAIL Fusion Protein with Specificity for Human EGFR Journal of Biological Chemistry ·Edwin Bremer,Douwe F. Samplonius,Linda van Genne,Marike H. Dijkstra,Bart Jan Kroesen,Lou F. M. H. de Leij,Wijnand Helfrich	2005	81
19	Exceptionally Potent Anti-Tumor Bystander Activity of an scFv:sTRAIL Fusion Protein with Specificity for EGP2 Toward Target Antigen-Negative Tumor Cells Neoplasia ·Edwin Bremer,Douwe F. Samplonius,Bart‐Jan Kroesen,Linda van Genne,Lou de Leij,Wijnand Helfrich	2004	46
20	Target cell‐restricted and ‐enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma‐associated antigen EGP2 International Journal of Cancer ·Edwin Bremer,Jos M.A. Kuijlen,Douwe F. Samplonius,Henning Walczak,Lou de Leij,Wijnand Helfrich	2003	75

About Douwe F. Samplonius

Douwe F. Samplonius is a scholar working on Immunology, Physiology and Oncology, having authored 39 papers that have together received 1.1k indexed citations. Recurring topics across this work include CAR-T cell therapy research (10 papers), Cell death mechanisms and regulation (10 papers), Immune Cell Function and Interaction (7 papers), Cancer Immunotherapy and Biomarkers (7 papers), Immunotherapy and Immune Responses (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and RNA Interference and Gene Delivery (4 papers). The work is most often cited by research in Immunology (570 citations), Oncology (387 citations) and Biotechnology (83 citations). Douwe F. Samplonius has collaborated with scholars based in Netherlands, China and United Kingdom. Frequent co-authors include Wijnand Helfrich, Edwin Bremer, Lou F. M. H. de Leij, Bram ten Cate, Robert J. van Ginkel, Marco de Bruyn, Valerie R. Wiersma, Lou de Leij, Hans W. Nijman and Bart‐Jan Kroesen. Their work appears in journals such as Journal of Biological Chemistry, Blood and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact